Drug
Felzartamab
Felzartamab: highest development phase Phase 3, developed by Biogen. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Felzartamab NCT07444489 | Phase 3 | Antibody-mediated Rejection |
| Felzartamab NCT06935357 | Phase 3 | Immunoglobulin A Nephropathy (IgAN) |
| Felzartamab NCT06962800 | Phase 3 | Primary Membranous Nephropathy |
| Felzartamab NCT05065970 | Phase 2 | Immunoglobulin A (IgA) Nephropathy |
| Felzartamab NCT07722546 | Phase 2 | Graves' Disease |
| Felzartamab NCT07889362 | Phase 2 | Immunoglobulin A Nephropathy |
| Felzartamab NCT07219043 | Phase 2 | Microvascular Inflammation |
Latest
No recent events.
Follow Felzartamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.